IRF7
Interferon regulatory factor 7
Also known as: IRF7_HUMAN
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- Q92985
- Gene
- IRF7
- Ensembl
- ENSG00000185507
- Chromosome
- 11
- Canonical length
- 503 aa
- Protein class
- Disease related genes, Human disease related genes, Predicted intracellular proteins, Transcription factors
- Subcellular location
- Nucleoplasm,Cytosol
- Quaternary structure
- Homodimer
OverviewNCBI Gene
This gene encodes interferon regulatory factor 7, a member of the interferon regulatory transcription factor (IRF) family. It has been shown to play a role in the transcriptional activation of virus-inducible cellular genes, including interferon beta chain genes. Inducible expression of IRF7 is largely restricted to lymphoid tissue. The encoded protein plays an important role in the innate immune response against DNA and RNA viruses. [provided by RefSeq, Jul 2021]
Canonical amino-acid sequenceUniProt
503 residues, UniProt reviewed canonical sequence.
>Q92985|IRF7
1 MALAPERAAP RVLFGEWLLG EISSGCYEGL QWLDEARTCF RVPWKHFARK DLSEADARIF
61 KAWAVARGRW PPSSRGGGPP PEAETAERAG WKTNFRCALR STRRFVMLRD NSGDPADPHK
121 VYALSRELCW REGPGTDQTE AEAPAAVPPP QGGPPGPFLA HTHAGLQAPG PLPAPAGDKG
181 DLLLQAVQQS CLADHLLTAS WGADPVPTKA PGEGQEGLPL TGACAGGPGL PAGELYGWAV
241 ETTPSPGPQP AALTTGEAAA PESPHQAEPY LSPSPSACTA VQEPSPGALD VTIMYKGRTV
301 LQKVVGHPSC TFLYGPPDPA VRATDPQQVA FPSPAELPDQ KQLRYTEELL RHVAPGLHLE
361 LRGPQLWARR MGKCKVYWEV GGPPGSASPS TPACLLPRNC DTPIFDFRVF FQELVEFRAR
421 QRRGSPRYTI YLGFGQDLSA GRPKEKSLVL VKLEPWLCRV HLEGTQREGV SSLDSSSLSL
481 CLSSANSLYD DIECFLMELE QPALocalizationUniProt · AlphaFold · HPA
Whether an antibody against IRF7 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Intracellular
- Secreted
- No
- Transmembrane segments
- 0
- Mean surface accessibility (rSASA)
- 0.44
- Highest tissue expression
- 39 nTPM
Expression across tissuesHPA
Tissue
- liver: 39 nTPM
- spleen: 34 nTPM
- lung: 15 nTPM
- small intestine: 15 nTPM
- esophagus: 13 nTPM
- kidney: 12 nTPM
Single-cell type
- pdcs: 790 nCPM
- esophageal apical cells: 55 nCPM
- extravillous trophoblasts: 38 nCPM
- cdc: 33 nCPM
- late spermatids: 32 nCPM
- breast lactating cells: 31 nCPM
Immune cell
- plasmacytoid DC: 598 nTPM
- non-classical monocyte: 50 nTPM
- intermediate monocyte: 46 nTPM
- eosinophil: 31 nTPM
- myeloid DC: 24 nTPM
- naive B-cell: 21 nTPM
Brain region
- medulla oblongata: 3.4 nTPM
- choroid plexus: 3.3 nTPM
- pons: 2.9 nTPM
- cerebral cortex: 1.8 nTPM
- midbrain: 1.8 nTPM
- cerebellum: 1.7 nTPM
DiseaseUniProt · ClinVar · IEDB · PubMed
Four sources answering four different questions about IRF7.
Disease | AllUniProt
Conditions IRF7 is implicated in, by any mechanism.
- Immunodeficiency 39, susceptibility to viral infections (IMD39) MIM:616345
Disease | GeneticClinVar
1 pathogenic / likely-pathogenic of 782 ClinVar records.
Conditions with pathogenic or likely-pathogenic variants.
- Immunodeficiency 39
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 1.57
- gnomAD pLI
- 0
- gnomAD missense Z
- -0.85
- DepMap mean gene effect
- 0.03
- DepMap dependency class
- none
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 4% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
- cytoplasmic pattern recognition receptor signaling pathway
- defense response to virus
- DNA damage response
- immune system process
- immunoglobulin mediated immune response
- innate immune response
- MDA-5 signaling pathway
- negative regulation of macrophage apoptotic process
- negative regulation of transcription by RNA polymerase II
- positive regulation of DNA-templated transcription
- positive regulation of interferon-alpha production
- positive regulation of interferon-beta production
- positive regulation of transcription by RNA polymerase II
- positive regulation of type I interferon production
- positive regulation of type I interferon-mediated signaling pathway
- regulation of adaptive immune response
- regulation of immune response
- regulation of monocyte differentiation
- regulation of MyD88-dependent toll-like receptor signaling pathway
- regulation of transcription by RNA polymerase II
- regulation of type I interferon production
- response to virus
- type I interferon-mediated signaling pathway
- establishment of viral latency
- regulation of MyD88-independent toll-like receptor signaling pathway
Molecular functions
- DNA binding
- DNA-binding transcription factor activity, RNA polymerase II-specific
- RNA polymerase II cis-regulatory region sequence-specific DNA binding
- sequence-specific double-stranded DNA binding
Cellular components
Protein domainsUniProt · Pfam · InterPro
- Interferon regulatory factor, DNA-binding domain
- SMAD/FHA domain superfamily
- SMAD-like domain superfamily
- Interferon regulatory factor-3
- Interferon regulatory factor, conserved site
- Winged helix-like DNA-binding domain superfamily
- Winged helix DNA-binding domain superfamily
- Interferon regulatory factor transcription factor
- Interferon-regulatory factor 3
KeywordsUniProt
InteractionsUniProt · HPA
Protein binding partners of IRF7 in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads IRF7 as an antibody target. Whether an autoantibody or antibody against IRF7 could matter depends on whether native IRF7 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
IRF7 is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.
Annotation status
The present source text does not explicitly label IRF7 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...